

October 29, 2009

XANODYNE RAISES \$50 MILLION IN EQUITY FINANCING

NEWPORT, K.Y. (October 29, 2009) -- Xanodyne Pharmaceuticals, Inc., an integrated pharmaceutical company with both development and commercial capabilities focused on healthcare and pain management, announced today the completion of \$50 million in equity financing. The round was led by Longitude Capital with participation from new investors Skandia and Capital. Other current investors that participated in the financing include MPM Capital, L. Investments' sponsored funds, Perseus-Soros Biopharmaceutical Fund, Blue Chip Venture HealthCare Ventures, LLC, and Union Springs, LLC. Aquilo Partners, L.P., a life science investor, acted as the exclusive placement agent for the financing.

Michael J. Valentino, President and CEO commented, "I am extremely pleased to have secured additional financial resources which will be used to support our ongoing development and commercialization strategy for our emerging product portfolio."

In June 2009, Xanodyne received Food and Drug Administration (FDA) approval for Zipsor[®] (potassium) Liquid Filled Capsules, a new treatment option for relief of mild to moderate pain in adults (18 years of age or older). Zipsor was launched nationally to physicians and patients in September.

In addition, the company expects FDA action soon on Lysteda[™] (formerly XP12B), an oral NSAID product under priority review. If approved, Lysteda would be the first and only oral NSAID agent indicated specifically for the treatment of women suffering from cyclic heavy menstrual bleeding.

Valentino added, "The continued commitment from our investor groups allows us to remain aggressively executing our product commercialization plans and optimizing the other assets in our portfolio."

About Xanodyne

Xanodyne Pharmaceuticals, Inc., which commenced operations in 2001, is an integrated pharmaceutical company with both development and commercial capabilities focused on healthcare and pain management. Xanodyne markets a portfolio of products consisting of pharmaceuticals and a line of prenatal vitamins. Additionally, Xanodyne is advancing a pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas.

Investor/Media Contact: Rita O'Connor (859) 371-6383

Source: Xanodyne Pharmaceuticals, Inc.